TOLECTIN DS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOLECTIN DS (TOLECTIN DS).
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
| Metabolism | Hepatic metabolism primarily via oxidation and conjugation (glucuronidation); minor involvement of CYP450 enzymes. |
| Excretion | Primarily renal, 95% of a dose excreted in urine as glucuronide conjugates and oxidative metabolites; less than 5% fecal. |
| Half-life | Terminal elimination half-life approximately 1 hour; clinical context: requires frequent dosing every 6-8 hours due to short half-life. |
| Protein binding | Approximately 99% bound to plasma albumin. |
| Volume of Distribution | 0.1-0.2 L/kg; indicates distribution primarily in extracellular fluid and plasma. |
| Bioavailability | Oral: approximately 100% (well absorbed). |
| Onset of Action | Oral: 30-60 minutes to analgesia; anti-inflammatory effect within a few days to 2 weeks. |
| Duration of Action | Oral: 4-6 hours for analgesia; anti-inflammatory effect may persist longer with regular dosing. |
| Molecular Weight | 373.38 |
400 mg orally three times daily; maximum dose 1800 mg/day.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-89 mL/min: no adjustment needed. GFR < 30 mL/min: caution, reduce dose by 50% or increase interval to every 12 hours. Not recommended in severe renal failure. |
| Liver impairment | Child-Pugh class A: no adjustment needed. Child-Pugh class B or C: avoid use due to increased risk of hepatotoxicity. |
| Pediatric use | Children >=2 years: starting dose 20 mg/kg/day orally in 3-4 divided doses; maintenance dose 15-30 mg/kg/day. Maximum 30 mg/kg/day or 1800 mg/day, whichever is less. |
| Geriatric use | Initiate at lowest effective dose; monitor renal function and adjust accordingly. Consider dose reduction by 25-50% in elderly due to increased risk of GI bleeding and renal impairment. |
| 1st trimester | Avoid use during first trimester due to risk of cardiovascular and other congenital malformations associated with NSAID use. |
| 2nd trimester | Use only if clearly needed. May cause oligohydramnios and premature closure of ductus arteriosus if used for prolonged periods. |
| 3rd trimester | Contraindicated in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for TOLECTIN DS (TOLECTIN DS).
| Placental transfer | Crosses placenta; detectable in fetal plasma. Animal studies show placental transfer. |
| Breastfeeding | Excreted into breast milk in low amounts. Considered compatible with breastfeeding by the American Academy of Pediatrics, but monitor infant for potential adverse effects such as rash, gastrointestinal bleeding, or platelet dysfunction. |
■ FDA Black Box Warning
Cardiovascular thrombotic events, including myocardial infarction and stroke, can occur with NSAIDs. Increased risk of serious gastrointestinal adverse events such as bleeding, ulceration, and perforation.
| Serious Effects |
Hypersensitivity to tolmetin or any componentHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsCoronary artery bypass graft (CABG) perioperative painThird trimester pregnancy
| Precautions | Cardiovascular risk, gastrointestinal risk, renal toxicity, hepatic effects, anaphylactoid reactions, skin reactions (including Stevens-Johnson syndrome), hematologic effects, and use in pregnancy (avoid in third trimester). |
| Food/Dietary | Take with food or milk to minimize GI irritation. Avoid alcohol due to increased risk of GI bleeding. No other significant food interactions. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: increased risk of cardiac defects and gastroschisis; third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment; avoid in pregnancy especially after 30 weeks. |
| Fetal Monitoring | Monitor renal function, amniotic fluid volume, and ductal patency via fetal echocardiography if used after 20 weeks' gestation. |
| Fertility Effects | May impair female fertility via inhibition of prostaglandin synthesis affecting ovulation; reversible upon discontinuation. |
| Clinical Pearls | TOLECTIN DS is a nonsteroidal anti-inflammatory drug (NSAID) used for rheumatoid arthritis and osteoarthritis. Monitor renal function and gastrointestinal bleeding risk. Avoid use in patients with aspirin-sensitive asthma. Use lowest effective dose for shortest duration. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not crush or chew the DS (double-strength) tablet; swallow whole. · Avoid alcohol while taking this medication. · Seek medical attention for signs of GI bleeding (black/tarry stools, vomiting blood). · Report unexplained weight gain or edema to your doctor. |